Clinuvel Pharmaceuticals Ltd (ASX: CUV) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Clinuvel Pharmaceuticals Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Clinuvel Pharmaceuticals Ltd (ASX: CUV)
Latest News
Share Market News
3 beaten up shares you might be surprised to learn are still part of the ASX 200
Share Market News
ASX 200 (ASX:XJO) midday update: Magellan jumps on buyback news, travel shares take off
Share Gainers
Why Clinuvel, Dicker Data, Healius, and Uniti shares are rising today
Healthcare Shares
Why is the Clinuvel (ASX:CUV) share price zooming 6% higher today?
Share Market News
Why BHP, Clinuvel, Latitude, and Peet shares are pushing higher
Share Market News
ASX 200 (ASX:XJO) midday update: Afterpay sinks again, BHP and Rio rise
Share Fallers
These were the worst performing ASX 200 shares last week
Share Fallers
Here are 6 of the worst performing ASX shares of November
Frequently Asked Questions
-
Clinuvel Pharmaceuticals listed on the ASX in 2001 and only recently declared a profit for the first time in FY2017. Since then, the company went on to achieve increased profits across both FY2018 and FY2019. It also distributed final dividends of 2 cents and 2.5 cents per share for FY2018 and FY2019 respectively. As at 17 June 2020, Clinuvel has made no announcements regarding the status of its FY2020 dividend payment.
-
Having only started paying dividends over the last couple of years, Clinuvel Pharmaceuticals does not currently offer a dividend reinvestment plan.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
02 Sep 2021 | $0.0250 | 0.00% | Final | 17 Sep 2021 |
03 Sep 2020 | $0.0250 | 0.00% | Final | 18 Sep 2020 |
04 Sep 2019 | $0.0250 | 0.00% | Final | 19 Sep 2019 |
21 Sep 2018 | $0.0200 | 0.00% | Final | 08 Oct 2018 |
CUV ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Limited (CUV) is a global biopharmaceutical company that develops drugs for the treatment of a range of skin disorders. The company’s flagship product is Scenesse, a drug designed for the treatment of erythropoietic protoporphyria (EPP). EPP is a rare metabolic disorder which causes burns after brief exposure to visible light, especially sunlight. It is estimated that there are 5,000 to 10,000 EPP patients worldwide.
Clinuvel is also seeking to progress the use of Scenesse for the treatment of vitiligo, a skin disorder characterised by the appearance of white to off-white skin patches due to the loss of melanin production.
The company’s history dates back to 1987 when university researchers devised an idea of synthesising human hormones to protect the skin. Clinuvel shares have been listed on the ASX since 2001 and as a biopharmaceutical company, the Clinuvel share price can often be particularly volatile, bouncing around in response to announcements such as clinical trials and new launches.
CUV Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
16 May 2022 | $16.75 | $0.14 | 0.84% | 129,859 | $16.66 | $16.99 | $16.51 |
13 May 2022 | $16.61 | $1.97 | 13.46% | 238,842 | $14.75 | $16.61 | $14.75 |
12 May 2022 | $14.64 | $-0.99 | -6.33% | 111,877 | $15.46 | $15.57 | $14.55 |
11 May 2022 | $15.63 | $0.00 | 0.00% | 129,669 | $15.63 | $16.27 | $15.01 |
10 May 2022 | $15.63 | $0.50 | 3.30% | 164,482 | $15.00 | $15.84 | $14.50 |
09 May 2022 | $15.13 | $-0.44 | -2.83% | 103,139 | $15.57 | $15.90 | $15.11 |
06 May 2022 | $15.57 | $-0.73 | -4.48% | 105,826 | $15.70 | $15.94 | $15.46 |
05 May 2022 | $16.30 | $0.54 | 3.43% | 94,900 | $16.10 | $16.43 | $15.91 |
04 May 2022 | $15.76 | $-0.38 | -2.35% | 78,501 | $16.83 | $16.85 | $15.74 |
03 May 2022 | $16.14 | $0.25 | 1.57% | 92,192 | $15.96 | $16.73 | $15.96 |
02 May 2022 | $15.89 | $-0.67 | -4.05% | 84,746 | $16.19 | $16.39 | $15.61 |
29 Apr 2022 | $16.56 | $0.49 | 3.05% | 101,952 | $16.20 | $16.56 | $15.92 |
28 Apr 2022 | $16.07 | $0.01 | 0.06% | 96,856 | $16.26 | $16.61 | $15.91 |
27 Apr 2022 | $16.06 | $-0.23 | -1.41% | 94,854 | $16.07 | $16.40 | $15.88 |
26 Apr 2022 | $16.29 | $-0.93 | -5.40% | 153,384 | $17.04 | $17.20 | $16.05 |
22 Apr 2022 | $17.22 | $-0.68 | -3.80% | 84,440 | $17.85 | $17.85 | $17.13 |
21 Apr 2022 | $17.90 | $0.82 | 4.80% | 118,153 | $17.56 | $18.24 | $17.38 |
20 Apr 2022 | $17.08 | $-0.50 | -2.84% | 106,434 | $17.80 | $17.97 | $17.08 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
10 May 2022 | Philippe Wolgen | Buy | 1 | $16,143 | On-market trade. |
06 May 2022 | Andrew Likierman | Buy | 1 | $9,068 | On-market trade. IN GBP |
22 Mar 2022 | Philippe Wolgen | Sell | 55 | $1,132,006 | On-market trade. |
25 Feb 2022 | Jeffrey Rosenfeld | Buy | 485 | $9,263 | On-market trade. |
14 Jan 2022 | Brenda Shanahan | Expiry | 25 | $628,250 | As advised by the company. Lapse of conditional performance rights |
30 Jun 2021 | Philippe Wolgen | Sell | 122 | $3,748,582 | On-market trade. |
24 Jun 2021 | Brenda Shanahan | Sell | 25 | $691,771 | On-market trade. |
31 May 2021 | Philippe Wolgen | Sell | 102 | $3,127,366 | On-market trade. |
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Ms Brenda Mary Shanahan | Non-Executive Director | Dec 2007 | Mrs Shanahan has more tha 20 year's of experience in medical R&D and commercialisation. She is currently a non executive director of Phoslock Water Solutions Ltd. |
Mrs Susan (Sue) Smith | Non-Executive Director | Sep 2019 | Mrs Smith is the Chief Executive Officer of the Independent Doctors Federation, a membership organisation representing practicing physicians within the UK independent healthcare sector. Mrs Smith also manages a consultancy business, providing advisory services to a range of healthcare organisations, investors and boards of directors. Prior to her current roles Mrs Smith has a career, serving for 14 years as Chief Executive Officer of The Princess Grace Hospital, London, and 11 years as the Chief Executive Officer of The Portland Hospital for Women and Children, London. Based in London, Mrs Smith is also Non-Executive Board Chair of Women's Health (London West One) Ltd, a specialist medical practice, Non-Executive Director of Elite Medicine Ltd, a precision medicine company, and a Trustee of the HCA International Foundation. |
Dr Philippe J Wolgen | Chief Executive OfficerManaging Director | Dec 2005 | Dr Wolgen is currently leading the Group's expansion, with an immediate focus on the US and the further development of the product pipeline for various market segments. His focus has been to establish a professional management team to execute the corporate objectives set and prepare next generation of managers. |
Mr Willem A Blijdorp | Non-Executive DirectorNon-Executive Chairman | Jan 2015 | Mr Blijdorp is an internationally recongnised entrepreneur who has helped build the B&S Group, one of the largest global trading houses, in a period spanning three decades. Willem now serves on its Supervisory Board and is a majority shareholder, focussing on the Group's development and expansion strategy. Mr Blijdorp was recognised for his expertise in merger and acquisitions and commercial leadership as the Ernst & Young Entrepreneur of the Year in the Netherlands, and runner-up in its European Union awards. He is a Chair member of Remuneration and Nomination committee. He is also member of the Audit and Risk Committee. |
Dr Karen Agersborg | Non-Executive Director | Jan 2018 | Dr Agersborg had previously worked at Reading Hospital, West Reading and at Suburban Hospital, Norristown as Clinical Endocrinologist and served as Chief, Endocrinology, Diabetes, Metabolism at Chestnut Hill Hospital. Dr Agersborg had a career in managing commercial sales & distribution at Wyeth Pharmaceuticals (formerly Ayerst Laboratories). Dr Agersborg is also integral to setting US commercial strategy, pending US approval of SCENESSE, a decision on an approval expected later in 2019. |
Dr Jeffrey Rosenfeld | Non-Executive Director | Nov 2019 | Dr Rosenfeld has experience in senior healthcare and research executive roles and career in the Australian Army Reserve. He was the Founding Director of Monash University Institute of Medical Engineering (MIME-Melbourne) and acted as Board Chair for the Security and Health Executive Leadership Institute at The University of Melbourne. For 15 years Dr Rosenfeld was Director of Neurosurgery at the Alfred Hospital, concurrently holding for nine years the position of Professor and Head of the Department of Surgery at Monash University. Dr Rosenfeld is an active member of the Melbourne community and is involved in various charitable causes. He has devoted much of his time to the Australian-Aid funded Pacific Islands Project for transfer of clinical skills and knowhow to healthcare professionals in Papua New Guinea, Fiji and the Solomon Islands. One of Australia's senior and experienced military surgeons, Dr Rosenfeld served on eight deployments to Rwanda, Bougainville, East Timor, the Solomon Islands and Iraq. Having attained the rank of Major General, Dr Rosenfeld is also a former Surgeon General of the Australian Defence Force and remains active in defence and veterans' affairs organisations.In 2018, he received the International Lifetime Recognition Award of the American Association of Neurological Surgeons. |
Sir Andrew Likierman | Non-Executive Director | Apr 2022 | Sir Likierman has experience between public, private and academic positions. He is Professor of Management Practice at the London Business School and was its Dean from 2009 to 2017. He is currently working on the role of judgement in management, with his work used by many organisations. In the private sector, he served as non-executive Director of Times Newspaper Holdings Ltd, Monument Bank, Barclays Bank plc, quoted insurance Lloyds underwriter Beazley plc, Applied Intellectual Capital plc, and market research firm MORI Ltd. Among many roles in the public sector, he worked in the UK Cabinet Office, and spent 11 years as Head of the UK Government Financial Management Service, during five of which he was also the Chief Financial Officer of the UK Treasury (Finance Ministry). He was knighted for public service in 2001. He has also served as non-executive Director at the Bank of England, non-executive Chair of the (UK) National Audit Office and non-executive Director and Vice-Chairman of the Tavistock and Portman NHS Trust. |
Mr Darren Keamy | Chief Finance OfficerCompany Secretary | Dec 2005 | - |
Darren Keamy | Chief Finance OfficerCompany Secretary | - |
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited | 11,368,759 | 30.24% |
Bnp Paribas Nominees Pty Ltd Acf Clearstream | 5,942,326 | 6.31% |
BNP Paribas Nominees Pty Ltd Six Sis Ltd (Drp A/C) | 5,130,894 | 5.99% |
J P Morgan Nominees Australia Pty Limited | 3,819,117 | 5.68% |
Acn 108 768 896 Pty Ltd | 2,780,040 | 4.08% |
Ender 1 Llc | 2,590,824 | 3.89% |
Citicorp Nominees Pty Limited | 2,385,285 | 2.79% |
Dr Philippe Jacques Wolgen | 975,511 | 2.35% |
BNP Paribas Nominees Pty Ltd (Ib Au Noms Retail Client Drp) | 856,796 | 1.79% |
M Badcock And P Chu Superannuation Fund Pty Ltd | 632,947 | 1.75% |
National Nominees Limited (Db A/C) | 603,990 | 1.75% |
Dr Mark Edwin Badcock | 547,563 | 1.60% |
BNP Paribas Noms Pty Ltd (Drp) | 452,391 | 1.58% |
BNP Paribas Nominees Pty Ltd (Agency Lending Drp A/C) | 271,419 | 1.17% |
BNP Paribas Noms (Nz) Ltd (Drp) | 241,539 | 1.14% |
Merrill Lynch (Australia) Nominees Pty Limited | 238,237 | 0.98% |
Mr David William Trevorrow | 222,222 | 0.87% |
Truebell Capital Pty Ltd (Trubell Investment Fund) | 200,000 | 0.82% |
HSBC Custody Nominees (Australia) Limited A/C 2 | 192,758 | 0.82% |
Mr David John Lewis | 187,000 | 0.80% |